Bristol Myers Squibb Stock Jumps on Report of $400 Billion Merger Talks With Big Rival - Barron's
- Bristol Myers Squibb Stock Jumps on Report of $400 Billion Merger Talks With Big Rival Barron's
- AstraZeneca held talks with Bristol Myers Squibb on $400 billion megadeal, source says Reuters
- Struggling to make sense of AstraZeneca-BMS Financial Times
- Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea Fierce Pharma
- Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure? Yahoo Finance
Related Markets
All MarketsMarket data may be delayed. Not financial advice.
💡 AI analysis provides alternative perspectives on current events